Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 7—July 2023
Research

Sensitivity to Neutralizing Antibodies and Resistance to Type I Interferons in SARS-CoV-2 R.1 Lineage Variants, Canada

Rajesh Abraham Jacob, Ali Zhang1, Hannah O. Ajoge1, Michael R. D'Agostino1, Kuganya Nirmalarajah, Altynay Shigayeva, Wael L. Demian, Sheridan J.C. Baker, Hooman Derakhshani, Laura Rossi, Jalees A. Nasir, Emily M. Panousis, Ahmed N. Draia, Christie Vermeiren, Jodi Gilchrist, Nicole Smieja, David Bulir, Marek Smieja, Michael G. Surette, Andrew G. McArthur, Allison J. McGeer, Samira Mubareka, Arinjay Banerjee, Matthew S. Miller, and Karen MossmanComments to Author 
Author affiliations: McMaster University, Hamilton, Ontario, Canada (R.A. Jacob, A. Zhang, H.O. Ajoge, M.R. D'Agostino, W.L. Demian, S.J.C. Baker, L. Rossi, J.A. Nasir, E.M. Panousis, A.N. Draia, D. Bulir, M. Smieja, M.G. Surette, A.G. McArthur, M.S. Miller, K. Mossman); Sunnybrook Research Institute, Toronto, Ontario, Canada (K. Nirmalarajah, S. Mubareka); University of Toronto, Toronto (A. Shigayeva, C. Vermeiren, A.J. McGeer, S. Mubareka, A. Banerjee); University of Manitoba, Winnipeg, Manitoba, Canada (H. Derakhshani); Research Institute of St. Joe’s Hamilton, Hamilton (J. Gilchrist, N. Smieja, D. Bulir); Vaccine and Infectious Disease Organization, Saskatoon, Saskatchewan, Canada (A. Banerjee); University of Saskatchewan, Saskatoon (A. Banerjee); University of Waterloo, Waterloo, Ontario, Canada (A. Banerjee); University of British Columbia, Vancouver, British Columbia, Canada (A. Banerjee)

Main Article

Table 2

Summary of neutralization of SARS-CoV-2 isolates from study of sensitivity to neutralizing antibodies and resistance to type I interferons in SARS-CoV-2 R.1 lineage variants, Canada

SARS-CoV-2 isolates Sensitive isolate Adjusted p value
Wave 1: 15,000 PFU
SB3 vs. R.1 645 NA NS
SB3 vs. B.1.351 NA NS
R.1 645 vs. B.1.351
 R.1645
 0.0186
Wave 1: 1,500 PFU
SB3 vs. R.1 645 NA NS
SB3 vs. B.1.351 SB3 0.0243
R.1 645 vs. B.1.351
 R.1 645
 0.0011
Wave 1: 150 PFU
SB3 vs. R.1 645 R.1 645 0.0141
SB3 vs. B.1.351 SB3 0.0066
R.1 645 vs. B.1.351
 R.1 645
 0.0022
Wave 3: 15,000 PFU
SB3 vs. R.1 645 R.1 645 0.0391
SB3 vs. B.1.351 NA NS
R.1 645 vs. B.1.351
 R.1 645
 0.0385
Wave 3: 1,500 PFU
SB3 vs. R.1 645 R.1 645 0.0079
SB3 vs. B.1.351 NA NS
R.1 645 vs. B.1.351
 R.1 645
 0.0093
Wave 3: 150 PFU
SB3 vs. R.1 645 R.1 645 0.0038
SB3 vs. B.1.351 NA NS
R.1 645 vs. B.1.351 R.1 645 0.0053

*NA, not applicable; NS, not significant; PFU, plaque-forming units.

Main Article

1These authors contributed equally to this article.

Page created: May 08, 2023
Page updated: June 20, 2023
Page reviewed: June 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external